Abstract
Immunotherapy is becoming another possible alternative in the treatment of lung cancer. It is a completely different method of treating cancer which is not directed to the tumor itself, but to the immune system.
Surface antigens present on tumor cells may be an effective and specific therapeutic targets and strategies based on antibodies inhibiting immune check-points significantly improves the anti-tumor immune response. Monoclonal antibody blocking CTLA-4 (cytotoxic T-lymphocyte antigen) and PD-1 receptor (protein programmed cell death) and its ligand PD-L1 showed clinical efficacy and nivolumab (anti-PD-1) was approved in 2nd line treatment squamous non-small cell lung cancer.
Key words: bronchogenic carcinoma - vaccines - immune checkpoints The author declares she has no potential conflicts of interest concerning drugs, products, or services used in the study.